The Quiet Revolution in the Lab: How Anthropic is Changing Drug Development with Claude
Developing new drugs is a laborious, expensive, and excruciatingly long process, which often gets stuck in endless bureaucracy and complex data analysis. Recently, Anthropic revealed that it is not just providing tools for others, but is entering the field of drug development itself, integrating its model, Claude, into the very heart of scientific research [1, 2].
Beyond AI as a mere assistant
Anthropic announced partnerships with six leading organizations in the biotech and pharma sectors, including Bristol Myers Squibb, BigHat Biosciences, and Enveda [1, 9]. The goal is clear: to use Claude to shorten the path from the lab to the patient. The company even launched Claude Science, a dedicated workspace for scientists that enables running complex analyses, working with datasets, and generating verifiable scientific reports [10].
The data speaks: 89% time savings
One of the biggest barriers in drug development is regulatory and technical paperwork. This is where Claude shows particularly impressive results:
- •Streamlining production processes: At Enveda, chemists used to spend up to 75% of their time on paperwork. With Claude, the time for reviewing production documents dropped from 25 hours to less than three – an improvement of 89% [1, 9].
- •Regulatory accuracy: Claude is not just faster, but also more thorough. In a review of a 1,061-page document, the model identified all the issues found by humans and additionally detected 7 more issues that had escaped their eyes [9].
- •Writing reports: A regulatory task that previously required three months of manual work was completed by Claude in a first draft in just four hours [1, 9].
Beyond paperwork: Molecule design and new discoveries
The use of Claude is not limited to administrative management. At Divergence Labs, for example, the model helped generate about 35,000 antibody designs in just one month, with some showing better performance than existing standard drugs [2]. Additionally, Anthropic itself has begun running internal research programs, including the discovery of a new enzyme system, which indicates that the company views biology as a strategic objective and not just a market for its tools [5, 6].
Summary and future outlook
It is important to emphasize: we are still in the early stages. Most of these projects are preclinical, meaning the drugs have not yet been tested in humans [2, 9]. However, the ability of large language models to perform "scientific reasoning" and process massive amounts of biological data is changing the rules of the game.
For developers and companies in the life sciences sector, the message is clear: artificial intelligence is no longer just "writing code" or "summarizing emails." It is becoming an active partner in research, one capable of accelerating processes that previously took years and turning them into months.
Additional sources for review: